Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass.

[1]  S. Westaby.  Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extracorporeal circuit , 2004, Intensive Care Medicine.

[2]  D. Fairlie,et al.  Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. , 2002, The Journal of surgical research.

[3]  Anna J. Strachan,et al.  Inhibition of immune‐complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist , 2002, British journal of pharmacology.

[4]  I. Kluijt,et al.  A family with complement factor D deficiency. , 2001, The Journal of clinical investigation.

[5]  A. Undar,et al.  Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. , 2001, The Journal of thoracic and cardiovascular surgery.

[6]  John D Lambris,et al.  Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. , 2000, Clinical immunology.

[7]  John D Lambris,et al.  Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. , 2000, Immunopharmacology.

[8]  John D Lambris,et al.  Therapeutic Interventions in the Complement System , 2000, Contemporary Immunology.

[9]  J. Carr,et al.  The heparin-protamine interaction. A review. , 1999, The Journal of cardiovascular surgery.

[10]  G. Asimakopoulos.  Mechanisms of the systemic inflammatory response , 1999, Perfusion.

[11]  John D Lambris,et al.  Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation , 1998 .

[12]  T. Mollnes.  Complement and Biocompatibility , 1998, Vox Sanguinis.

[13]  John D Lambris,et al.  Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. , 1998, Blood.

[14]  T. Lint,et al.  Requirement for the alternative pathway as well as C4 and C2 in complement-dependent hemolysis via the lectin pathway. , 1998, Journal of immunology.

[15]  R. Colman,et al.  A baboon model for hematologic studies of cardiopulmonary bypass. , 1997, The Journal of laboratory and clinical medicine.

[16]  John D Lambris,et al.  Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. , 1996, Journal of immunology.

[17]  G. Hill.  The Inflammatory Response to Cardiopulmonary Bypass , 1996, International anesthesiology clinics.

[18]  W. Baumgartner,et al.  Inhibition of neutrophil adhesion during cardiopulmonary bypass. , 1994, The Annals of thoracic surgery.

[19]  G. von Bernuth,et al.  Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. , 1993, The Journal of thoracic and cardiovascular surgery.

[20]  J. Weiler,et al.  Cytokine and complement levels in patients undergoing cardiopulmonary bypass. , 1993, The Journal of thoracic and cardiovascular surgery.

[21]  T. Gardner,et al.  Inhibition of Neutrophil Adherence Improves Postischemic Ventricular Performance of the Neonatal Heart , 1993, Circulation.

[22]  S Westaby,et al.  Inflammatory response to cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[23]  G. Hubbard,et al.  Clinical parameters of the normal baboons (Papio species) and chimpanzees (Pan troglodytes). , 1993, Laboratory animal science.

[24]  J. Levy.  4 – Complement and Contact Activation , 1992 .

[25]  H. Redl,et al.  The cell in shock: the origin of multiple organ failure. , 1991, Resuscitation.

[26]  J. Atkinson,et al.  The mechanism of activation of the alternative pathway of complement by cell-bound C4b. , 1990, Molecular immunology.

[27]  J. Utley.  Pathophysiology of Cardiopulmonary Bypass: Current Issues , 1990, Journal of cardiac surgery.

[28]  W. Fraser,et al.  Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. , 1990, Clinical science.

[29]  T. Carlos,et al.  Membrane Proteins Involved in Phagocyte Adherence to Endothelium , 1990, Immunological reviews.

[30]  P. Libby,et al.  Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. , 1990, The Journal of clinical investigation.

[31]  J. Cavaillon,et al.  Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide‐stimulated monocytes and macrophages , 1990, European journal of immunology.

[32]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[33]  S. Khuri,et al.  The Effects of Complement Activation During Cardiopulmonary Bypass: Attenuation by Hypothermia, Heparin, and Hemodilution , 1988, Annals of surgery.

[34]  S. Clark,et al.  Multiple actions of interleukin 6 within a cytokine network. , 1988, Immunology today.

[35]  J. Cavaillon,et al.  C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. , 1987, Journal of immunology.

[36]  E. Fosse,et al.  Complement activation during major operations with or without cardiopulmonary bypass. , 1987, The Journal of thoracic and cardiovascular surgery.

[37]  A. Marty,et al.  Anaphylactic Reactions in Anesthesia and Intensive Care , 1986 .

[38]  E. Blackstone,et al.  Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. , 1986, The Annals of thoracic surgery.

[39]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, Thorax.

[40]  E. Blackstone,et al.  Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. , 1981, The New England journal of medicine.